-
Report details
-
0
Figures
-
67
Tables
-
1: Executive Summary
-
A Mix of Traditional and Emerging Testing Technologies
-
Market Drivers
-
The World Infectious Disease Testing Market
-
Major Findings of the Report
-
Scope and Methodology
-
2. Market Environment
-
Overview
-
Global Macroeconomic Environment
-
Global Economic Outlook
-
Per Capita Gross Domestic Product
-
Demographic Trends
-
Total Population
-
Age Distribution
-
Global Healthcare Trends
-
Health Expenditures
-
Hospitals
-
Physicians
-
Clinical Laboratories
-
Patient Activity
-
3. Infectious Disease IVD Products & Markets
-
Overview
-
Sexually Transmitted Diseases (STDs)
-
Chlamydia Trachomatis (chlamydia)
-
Human Papillomavirus (HPV)
-
Gonorrhea
-
Herpes Simplex Virus 2 (HSV-2)
-
Syphilis
-
Other Sexually Transmitted Disease (STD) IVD Products
-
Hepatitis IVD Products
-
HIV/AIDS IVD Products
-
Healthcare-Associated Infections (HAIs) IVD Products
-
Clostridium difficile (C. diff)
-
Sepsis
-
Methicillin-Resistant Staphylococcus Aureus (MRSA)
-
Vancomycin-Resistant Enterococcus (VRE)
-
Other HAIs
-
Antibiotic Susceptibility Testing (AST) Products
-
Influenza
-
Tuberculosis (TB)
-
TORCH
-
All Other Infectious Disease IVD Products
-
Malaria
-
Streptococcal Infections
-
Lyme Disease
-
Fungal Infections
-
Parasitic Conditions
-
Respiratory Syncytial Virus (RSV)
-
Emerging Infections
-
Dengue Fever
-
Additional Products
-
Global Infectious Disease IVD Demand by Major Product Group
-
Global Infectious Disease IVD Demand by Technology
-
Molecular Technologies
-
Immunoassays
-
Conventional Microbiology
-
Global Infectious Disease IVD Demand by Market
-
4. Global Markets
-
North America
-
United States
-
Canada
-
Mexico
-
Western Europe
-
Germany
-
France
-
United Kingdom
-
Italy
-
Spain
-
Other Western Europe
-
Asia/Pacific
-
China
-
Japan
-
India
-
South Korea
-
Australia
-
Other Asia/Pacific
-
Central & South America
-
Brazil
-
Other Central & South America
-
Eastern Europe
-
Russia
-
Other Eastern Europe
-
Middle East
-
Africa
-
Egypt
-
South Africa
-
Nigeria
-
All Other Countries & Territories
-
5. Company Profiles
-
ABL SA
-
Overview
-
Infectious Disease IVD Products
-
Abbott Laboratories
-
Overview
-
Infectious Disease IVD Products
-
Becton, Dickinson and Company (BD)
-
Overview
-
Infectious Disease IVD Products
-
bioMérieux Inc.
-
Overview
-
Infectious Disease IVD Products
-
Bio-Rad Laboratories, Inc.
-
Overview
-
Infectious Disease IVD Products
-
Curetis N.V.
-
Overview
-
Infectious Disease IVD Products
-
Danaher Corporation
-
Overview
-
Infectious Disease IVD Products
-
DiaSorin S.p.A.
-
Overview
-
Infectious Disease IVD Products
-
EKF Diagnostics Holdings plc
-
Fujirebio Inc.
-
Overview
-
Infectious Disease IVD Products
-
Grifols
-
Overview
-
Infectious Disease IVD Products
-
Hologic, Inc.
-
Overview
-
Infectious Disease IVD Products
-
InSilixa, Inc.
-
Meridian Bioscience, Inc.
-
Overview
-
Infectious Disease IVD Products
-
OraSure Technologies, Inc.
-
Overview
-
Infectious Disease IVD Products
-
Ortho-Clinical Diagnostics
-
Overview
-
Infectious Disease IVD Products
-
QIAGEN N.V.
-
Overview
-
Infectious Disease IVD Products
-
Quidel Corporation
-
Overview
-
Infectious Disease IVD Products
-
Roche
-
Overview
-
Infectious Disease IVD Products
-
Siemens AG
-
Overview
-
Infectious Disease IVD Products
-
T2 Biosystems, Inc.
-
Overview
-
Infectious Disease IVD Products
-
Thermo Fisher Scientific Inc.
-
Overview
-
Infectious Disease IVD Products
-
Trinity Biotech
-
Overview
-
Infectious Disease IVD Products
|
Infectious Disease Diagnostics: World Market Analysis: HIV/AIDS, Hepatitis, Tuberculosis, STDs, HAIs, ID/AST, Influenza, TORCH, Other
30 Apr 2019
Infectious disease testing comprises one of the largest and fastest growing applications served by the global in vitro diagnostics (IVD) industry. Most of the leading industry competitors as well as a sizable number of specialized IVD concerns are active in this product segment. The detection and characterization of infectious diseases hold promising worldwide growth potential as discussed in Kalorama’s Infectious Disease Diagnostics: World Market Analysis: HIV/AIDS, Hepatitis, Tuberculosis, STDs, HAIs, ID/AST, Influenza, TORCH, Other.
The World Infectious Disease Testing Market
Global demand for infectious disease testing products in 2018 had applications extending into nine major segments:
• Sexually transmitted diseases other than hepatitis and HIV/AIDS (including chlamydia, gonorrhea, herpes HSV-1 and HSV-2, human papillomavirus, syphilis, and trichomoniasis)
• Hepatitis
• HIV/AIDS
• Healthcare-associated infections (HAIs), including sepsis, MRSA, C. difficile, VRE, and others
• Antibiotic susceptibility testing
• Influenza
• Tuberculosis
• TORCH
• Others (including malaria, dengue fever, foodborne infections, Lyme disease, RSV, Strep A, and typhoid)
Infectious diseases are ailments caused by pathogenic microorganisms that invade the body, either directly or indirectly via afflicted carriers or contaminated sources. IVD tests for these conditions are designed to detect and identify the responsible pathogen, pinpoint its origin, and determine an appropriate antimicrobial therapy. Infectious disease IVD products include reagents, consumables, and instruments based primarily on immunoassays, molecular technologies, and conventional microbiology techniques. Specific types of tests are available for detecting hundreds of pathogenic conditions. The report examines the global demand for infectious disease IVD products, which is projected to increase as medical providers and healthcare organizations throughout the world heighten efforts to combat proliferating epidemic threats. Data provided include the following:
• World Infectious Disease Diagnostic Test Market, 2018-2026 ($ millions)
• Global Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Demand)
• Global Sexually Transmitted Disease (STD) IVD Demand by Test Type & Condition 2018 - 2026 (million dollars) (By Type of Test: Immunoassay, Molecular, Other; By Condition: Chlamydia, HPV, Gonorrhea, Herpes HSV-2, Syphilis, Other; Global STD IVD Demand)
• Global Hepatitis IVD Demand by Test Type 2018 - 2026 (million dollars) (Laboratory Tests, Blood Screening, POC Tests, Global Hepatitis IVDs)
• Global HIV/AIDS IVD Demand by Test Type 2018 - 2026 (million dollars) (Laboratory Tests, Blood Screening, POC Tests, Global HIV/AIDS IVDs)
• Global Healthcare-Associated Infections (HAIs) IVD Demand by Test Type & Condition 2018 - 2026 (million dollars) (By Type of Test: Immunoassay, Molecular, Microbiology; By Condition: C. diff, Sepsis, MRSA, VRE, Other HAIs; Global HAIs IVDs)
• Identification/Antibiotic Susceptibility Testing (ID/AST) Demand by Test Type 2018 - 2026 (million dollars) (Automated Tests, Manual Tests, Global ID/AST)
• Global Influenza Testing IVD Demand by Test Type 2018 - 2026 (million dollars) (Rapid ID Tests, Molecular Tests, Other Tests, Global Influenza IVDs)
• Global Tuberculosis (TB) Testing IVD Demand by Test Type 2018 - 2026 (million dollars) (Microbiology Tests, POC Tests, Molecular Tests, Global Tuberculosis IVDs)
• Global TORCH-Related IVD Demand 2018 - 2026 (million dollars)
• Global Other Infectious Disease IVD Demand by Condition 2018 - 2026 (million dollars) (Malaria, Streptococcal Infections, Lyme Disease, Fungal Infections, Parasitic Conditions, RSV, Emerging Infections, Dengue Fever, All Other Conditions, Global Other Infection IVDs)
The report also reviews various infectious disease testing technologies (immunoassay, microbiology, and molecular), markets (hospital and independent testing laboratories, POC and POL laboratories, blood banks, and other end-users), and products (reagents and consumables and instruments):
• Global Infectious Disease IVD Reagents, Consumables, & Instruments Demand 2018 - 2026 (million dollars) (Reagents/Consumables: STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH-Related, Other; Instruments & Systems; Global infection IVDs)
• Global Infectious Disease IVD Demand by Technology 2018 - 2026 (million dollars) (Immunoassay, Molecular, Microbiology & Related, Global Infection IVDs)
• Global Infectious Disease IVD Demand by End-Use Market 2018 - 2026 (million dollars) (Hospitals, Clinical Laboratories, POC Laboratories, Other Markets, Global Infection IVDs)
Geographic and Country Markets
Based on a high level of national health expenditures and patient activity and the large role played by private medical providers in the healthcare system, the U.S. will remain the largest and most diversified infectious disease testing market. China and India will provide the fastest growth among the developing economies as diagnostic capabilities are expanded and upgraded. Infectious Disease Diagnostics: World Market Analysis analyzes geographic and country markets, including North America: United States, Canada, Mexico; Western Europe; Asia/Pacific: China, Japan, Other; Central & South America; Eastern Europe; Middle East; and Africa.
• Global Infectious Disease IVD Demand by Country/Region 2018 - 2026 (million dollars) (North America: United States, Canada & Mexico; Western Europe; Asia/Pacific: China, Japan, Other; Cent & So America; Eastern Europe; Middle East; Africa; Total World)
• North America - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total N Amer)
• United States - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total US)
• Canada - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Canada)
• Mexico - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Mexico)
• Western Europe - Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total W. Europe)
• Germany - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Germany)
• France - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total France)
• United Kingdom - Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total UK)
• Italy - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Italy)
• Spain - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Spain)
• Other Western Europe - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total OWE)
• Other Western Europe - Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Netherlands, Belgium, Austria, Sweden, Switzerland, Denmark, Portugal, Norway, Greece, Ireland, Finland, All Other)
• Asia/Pacific - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Asia/Pacific)
• China - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total China)
• Japan - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Japan)
• India - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total India)
• South Korea - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total South Korea)
• Australia - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Australia)
• Other Asia/Pacific - Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Other Asia/Pacific)
• Other Asia/Pacific - Infectious Disease IVD Demand by Country 2018 - 2026 (million dollars) (Indonesia, Taiwan, Thailand, Philippines, Vietnam, Malaysia, Pakistan, Hong Kong, Singapore, New Zealand, All Other)
• Central & South America - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total C & S Amer)
• Brazil - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Brazil)
• Other Central & South America - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Other Cent & So Amer)
• Other Central & South America - Infectious Disease IVD Demand by Country 2018 - 2026 (million dollars) (Argentina, Colombia, Chile, Peru, Venezuela, All Other)
• Eastern Europe - Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total E Europe)
• Russia - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Russia)
• Other Eastern Europe - Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Other E. Europe)
• Other Eastern Europe - Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Poland, Romania, Czechia, Ukraine, Hungary, All Other)
• Middle East - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Middle East)
• Turkey - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Turkey)
• Other Middle East - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Other Middle East)
• Other Middle East - Infectious Disease IVD Demand by Country 2018 - 2026 (million dollars) (Iran, Saudi Arabia, Iraq, Israel, UAE, All Other)
• Africa - Infectious Disease IVD Demand by Product Group 2018 - 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Africa)
• Africa - Infectious Disease IVD Demand by Country 2018 - 2026 (million dollars) (Egypt, South Africa, Nigeria, All Other)
Market Drivers
The report looks at market drivers, including external market influences that are promoting the development and use of improved infectious disease diagnostics. Public health officials worldwide have begun to recognize the global nature of infectious diseases – they are no longer solely a problem of developing countries but touch the very fabric of the social and economic welfare of countries in the industrialized world as well. Over the long term, aging populations and problems posed by infectious diseases will strain healthcare resources in many countries.
Competitive Landscape
The report details the major competitors that are global market leaders in infectious disease testing products and technologies, including an overview and an outline of these company's infectious disease IVD products:
• ABL SA
• Abbott Laboratories
• Becton, Dickinson and Company (BD)
• bioMérieux Inc.
• Bio-Rad Laboratories, Inc.
• Curetis N.V.
• Danaher Corporation
• DiaSorin S.p.A.
• EKF Diagnostics Holdings plc
• Fujirebio Inc.
• Grifols
• Hologic, Inc.
• InSilixa, Inc.
• Meridian Bioscience, Inc.
• OraSure Technologies, Inc.
• Ortho-Clinical Diagnostics
• QIAGEN N.V.
• Quidel Corporation
• Roche
• Siemens AG
• T2 Biosystems, Inc.
• Thermo Fisher Scientific Inc.
• Trinity Biotech
The information presented herein is derived from publicly available information sources such as company, government, and medical organization reports. The analysis is based on the author's industry knowledge combined with literature searches and selected direct interviews with industry experts conducted previously.
Estimates in the report are based on an examination of epidemiological statistics, test pricing, annual reports of key competitors and regional sales, as well as Kalorama Information’s databases and economic composites.
Page Count: 202
|
This large-scope report has markets for several infectious disease testing categories including
Hep, HIV, TORCH, malaria, respiratory categories, rapid micro and traditional microbiology.
Markets are included for more than 20 countries.
More information about this product
Other Users Also Viewed
26 Aug 2020
What is the Size of IVD Market Segments? Who’s Winning? Who’s Merged? Who’s Launched Game-Changing Products?
One book definitively answers these questions, from a publisher that is focused on in vitro diagnostics. Now in its 13th edition, this…
|
